drugset / Trial / NCT04089657
Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy Regimens
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the efficacy and safety of Apatinib combined with PD-1 antibody Sintilimab for for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer
Timeline
- Start
- 2019-12-01
- Primary completion
- 2020-12-01
- Completion
- 2021-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | 500 mg | Oral |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |